Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences Inc. (IDYA) is a clinical-stage biotechnology leader advancing precision oncology therapies through synthetic lethality and biomarker-driven approaches. This news hub provides investors and researchers with timely updates on IDYA's innovative pipeline, strategic collaborations, and scientific advancements in targeting cancer vulnerabilities.
Access authoritative reporting on clinical trial progress, regulatory milestones, and research breakthroughs. Our curated collection includes press releases detailing IDEAYA's novel small molecule therapies, molecular diagnostic developments, and partnerships advancing personalized cancer treatments.
Key updates cover therapeutic candidates targeting DNA damage response pathways, tumor microenvironment innovations, and biomarker validation studies. Stay informed about IDEAYA's pioneering work in matched oncology therapies through verified financial filings and scientific disclosures.
Bookmark this page for consolidated access to essential IDYA developments, carefully sourced to support informed analysis of the company's position in the precision medicine landscape. Check regularly for new updates on clinical data readouts and strategic initiatives shaping the future of targeted cancer treatment.
IDEAYA Biosciences (NASDAQ: IDYA) has announced the granting of non-qualified stock options to four newly hired employees through its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved options to purchase 185,400 shares of common stock at an exercise price of $19.07 per share, matching the closing price on the Nasdaq Global Select Market on the grant date.
The stock options, granted under Nasdaq Listing Rule 5635(c)(4), feature a 10-year term with a four-year vesting schedule: 25% vesting after the first year, followed by monthly installments over three years. These inducement grants are specifically designed for new employees who were not previously with IDEAYA, contingent upon their continued service with the company.
IDEAYA Biosciences (NASDAQ:IDYA) has announced a successful FDA Type D meeting regarding the Phase 3 registrational trial design for darovasertib as neoadjuvant therapy for primary uveal melanoma (UM). The company plans to initiate the Phase 3 randomized trial in H1 2025, involving approximately 520 patients randomized 2:1 to treatment versus control.
The trial will include two cohorts: 120 enucleation-eligible UM patients and 400 plaque brachytherapy (PB) eligible patients. For the enucleation cohort, the primary endpoint is eye preservation rate, while the PB cohort's primary endpoint focuses on vision loss measurement. Both cohorts require no detriment to Event-Free-Survival as a secondary endpoint.
Darovasertib, a protein kinase C inhibitor, has received FDA Breakthrough Therapy Designation for neoadjuvant therapy in enucleation-recommended primary UM and Fast Track designation for combination therapy in metastatic UM. The trial will use 300mg BID darovasertib as the move-forward dose.
IDEAYA Biosciences (IDYA) has initiated a Phase 1/2 expansion study evaluating the combination of IDE397, its MAT2A inhibitor, with Trodelvy® in MTAP-deletion urothelial cancer (UC). The expansion is based on preliminary safety and clinical efficacy data.
IDE397 is a potent and selective small molecule inhibitor targeting MAT2A in solid tumors with MTAP-deletion, which affects approximately 26% of UC patients. The combination represents a potential first-in-class treatment approach for MTAP-deletion UC, addressing an unmet medical need with no currently approved targeted therapies.
A clinical program update on the IDE397-Trodelvy combination is expected in 2025. Additionally, IDEAYA plans to initiate a combination trial of IDE397 with IDE892, their MTA-cooperative PRMT5 inhibitor, in the second half of 2025.
IDEAYA Biosciences (NASDAQ: IDYA) has announced its participation in two upcoming investor relations events in April 2025. The company will participate in:
- The 2025 RBCCM Ophthalmology Conference on April 3rd, 2025 at 11:30 AM ET, featuring a fireside chat with CEO Yujiro S. Hata and CMO Darrin Beaupre
- The Stifel 2025 Virtual Targeted Oncology Forum on April 8th, 2025 at 12:00 PM ET, featuring CEO Yujiro S. Hata
Live audio webcasts will be available on the company's investor relations website, with replays accessible for 30 days after the events.
IDEAYA Biosciences (NASDAQ: IDYA) has received FDA Breakthrough Therapy Designation (BTD) for darovasertib, a first-in-class protein kinase C inhibitor, for neoadjuvant treatment of adult patients with primary uveal melanoma (UM) recommended for enucleation.
The BTD application was supported by Phase 2 clinical data showing 82% ocular tumor shrinkage rate and 61% eye preservation rate in UM patients. The company plans to initiate a Phase 3 registrational study in neoadjuvant UM in H1 2025.
Neoadjuvant UM represents a significant market opportunity with approximately 12,000 annual patients across North America, Europe, and Australia, with no FDA-approved systemic therapies currently available. The company plans to present updated clinical data, including efficacy, safety, and vision preservation metrics, at medical conferences in mid-2025 and H2 2025.
IDEAYA Biosciences (NASDAQ: IDYA) has announced the granting of inducement stock options to a new employee on March 27, 2025. The Compensation Committee approved non-qualified stock options to purchase 17,600 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $17.43 per share, matching the closing price of IDEAYA's stock on the Nasdaq Global Select Market on the grant date. These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting in monthly installments over the following three years, contingent on continued employment.
IDEAYA Biosciences (Nasdaq: IDYA) announced multiple presentations at AACR 2025, featuring IDE275 (GSK959), their Phase 1 Werner Helicase inhibitor. The drug, developed in partnership with GSK, will be highlighted in an oral presentation and three poster presentations.
IDE275 has shown potential as a best-in-class WRN inhibitor for treating MSI-H solid tumors, demonstrating selective preclinical efficacy. The drug targets significant patient populations, with MSI-H prevalence reported at approximately 31% in endometrial, 20% in colorectal, and 19% in gastric cancers.
Under the collaboration terms, GSK holds exclusive global rights and covers 80% of R&D costs, while IDEAYA maintains 20%. IDEAYA could receive a $10M milestone payment upon Phase 1 expansion, up to $465M in development milestones, and up to $475M in commercial milestones, plus 50% of U.S. net profits and tiered royalties on global non-U.S. sales.
IDEAYA Biosciences (NASDAQ: IDYA) has announced a research collaboration with ATTMOS to enhance its drug discovery capabilities for first-in-class oncology targets. The partnership aims to develop a physics-based computational platform for small molecule discovery, focusing on targets currently considered undruggable.
The collaboration will combine IDEAYA's expertise in structural biology and pharmaceutical drug discovery with ATTMOS's capabilities in computational chemistry, high-performance computing, and software development. The primary goal is to create a workflow solution for high-throughput absolute binding free energy perturbation predictions (ABFEP) of drug candidate molecules.
The initiative will utilize the Amber molecular dynamics suite for GPU-accelerated free energy simulations. IDEAYA will leverage its wet-lab drug discovery campaign data to train and evaluate ABFEP-based active learning cycles, enabling efficient screening of chemical libraries for novel small molecule ligands.
IDEAYA Biosciences (NASDAQ: IDYA) has announced the granting of non-qualified stock options to four newly hired employees through its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved options to purchase 125,600 shares of common stock on February 27, 2025.
The stock options were granted at an exercise price of $20.24 per share, matching the closing price of IDEAYA's stock on the Nasdaq Global Select Market on the grant date. These options come with a 10-year term and follow a four-year vesting schedule: 25% vesting after the first year, with the remaining 75% vesting in equal monthly installments over the following three years. The vesting is contingent upon continued employment with IDEAYA.
IDEAYA Biosciences reported its Q4 and full-year 2024 financial results, highlighting significant progress across its clinical pipeline. The company ended 2024 with approximately $1.1 billion in cash, cash equivalents, and marketable securities, expected to fund operations into at least 2028.
Key developments include over 230 patients enrolled in the registration-enabling trial for darovasertib in metastatic uveal melanoma, with median PFS readout targeted by year-end 2025. The company reported encouraging Phase 1 expansion results for IDE397 in MTAP-deletion cancers and selected clinical expansion doses for DLL3 TOP1i ADC IDE849.
Financial highlights for Q4 2024 include collaboration revenue of $7.0 million, R&D expenses of $140.2 million, and a net loss of $130.3 million. The full-year 2024 net loss was $274.5 million.
